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The pan-Canadian Oncology Drug Review (pCODR) was established in 2010  
to provide provinces and territories with recommendations on reimbursement 
for cancer drugs. OBJECTIVES: The objective of this study was to analyze  
the recommendations made by pCODR in its first year of operation and identify 
trends. METHODS: Clinical and economic guidance reports and 
recommendations, publically accessible at www.pcodr.ca were reviewed. 
RESULTS: Since pCODR began accepting submissions in 2011, ten of twenty 
applications have received recommendations. Of the seven positive 
recommendations, one suggested a more limited patient population than  
the one requested (Votrient - metastatic renal cell carcinoma). In six  
cases (Afinitor, Halaven, Jakavi, Sutent, Yervoy, Zelboraf), positive 
recommendations for the requested population were made, conditional on cost-
effectiveness being improved to an “acceptable” level; thus encouraging 
provincial negotiations on rebates. Three negative recommendations were made 
due to: a) limitations in evidence from open-label, phase two trials (Xalkori - 
advanced non-small cell lung cancer); b) modest progression-free survival, lack 
of statistically significant overall survival, lack of quality of life data and  
poor cost-effectiveness (Votrient - soft tissue sarcoma), and; c) unclear clinical 
benefit and an unacceptable cost-effectiveness model (Treanda - relapsed/ 
refractory chronic lymphocytic leukemia). In some cases the economic reviews 
by pCODR included modifications (i.e., shortening time horizons  
and modifying dose) to the submitted model. CONCLUSIONS: The 
recommendations from pCODR offer new insights into the future of oncology 
drug reimbursement in Canada. The probability of a positive recommendation 
appears to increase with randomized controlled trials, positive overall survival 
and comparators reflecting current care. Finally, the positive recommendations 
clearly support a continued provincial product listing agreement structure that 
includes rebates to lower cost-effectiveness. The new pCODR review process 
highlights the value of strong clinical data and robust cost-effectiveness 
modeling.  
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COMPARISON OF CANCER THERAPY REIMBURSEMENT DECISIONS MADE IN 
CANADA TO AUSTRALIA, SWEDEN AND THE UNITED KINGDOM  
Samjoo IA1, Grima DT2 
1Cornerstone Research Group Inc., Burlington, ON, Canada, 2Cornerstone Research Group, 
Burlington, ON, Canada  
OBJECTIVES: Our aim was to compare recommendations made by the pan-
Canadian Oncology Drug Review (pCODR) one year after its launch to other 
markets. METHODS: Publically accessible recommendations were reviewed: 
Canada (pCODR; www.pcodr.ca), UK (National Institute for Health and Clinical 
Excellence (NICE), www.nice.org.uk), Sweden (Dental and Pharmaceutical 
Benefits Agency (TLV), www.tlv.se), and Australia (Pharmaceutical Benefits 
Advisory Committee (PBAC), www.pbs.gov.au). RESULTS: pCODR had four 
product reviews in common with NICE, three with TLV, and five with PBAC. 
pCODR and NICE recommendations were most consistent; both positively 
recommended Votrient, Yervoy and Zelboraf. Inconsistency was observed for 
Halaven (pCODR = positive; NICE = negative). Compared to TLV, consistent 
positive recommendations were noted for Votrient and Yervoy, while 
inconsistency was observed for Zelboraf (pCODR = positive; TLV = negative). 
pCODR and PBAC were the least consistent; Votrient (renal cell carcinoma) 
received a positive recommendation and Votrient (soft tissue sarcoma) received 
a negative recommendation from both, Afinitor, Sutent, and Yervoy received 
positive recommendations by pCODR and negative recommendations by PBAC. 
Only two therapies were reviewed by all four groups: Votrient (renal cell 
carcinoma) which received a positive recommendation by all and Yervoy which 
received a positive recommendation by all, except PBAC. CONCLUSIONS: For 
products that were reviewed by pCODR and at least one other agency, the most 
consistency was observed with NICE. Discordance in recommendations may 
reflect process differences. For example, pCODR can positively recommend a 
product with acceptable clinical value conditional on improved cost-
effectiveness. However, the degree of improvement is not reviewed with the 
manufacturer; instead it is negotiated with the provincial reimbursement bodies. 
While other agencies, such as NICE, will specify a patient access scheme with the 
manufacturer as part of the recommendation process. In addition, pCODR is the 
only oncology-specific agency in these countries.  
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NOVEL REIMBURSEMENT MODELS FOR CANCER DRUG MARKET ACCESS (2010-
2013)  
Aggarwal S, Topaloglu H, Messenger M 
Novel Health Strategies, Bethesda, MD, USA  
OBJECTIVES: Cancer drugs are the world's highest selling category of therapeutic 
products. Due to their premium price and budget impact several new drug 
reimbursement models have been implemented worldwide by public and private 
payers. These models have potential implications for coverage and 
reimbursement of all branded products. This study reviewed recent cancer drug 
reimbursement models and developed lessons and implications for future 
products. METHODS: Reviewed cancer drug reimbursement schemes in 
developed and emerging markets. Interviewed payers and KOLs to develop 
lessons and implications for future products. RESULTS: Public and private payers 
worldwide have implemented several new models for cancer drug 
reimbursement to manage budgets and control costs. In the U.S., private payers 
are piloting single source compendia and third party protocols (eg. P4 Oncology) 
to limit off-label use of cancer drugs. In the UK, NICE has successfully negotiated 
lower price and discounts for the first few cycles of therapy. In Italy, AIFA has 
implemented registry based patient access for cancer drugs. In India, several 
manufacturers have implemented novel pricing strategy for the first few cycles 
of therapy. In Germany, IQWIG has proposed to use correlations between 
surrogate endpoints and patient relevant outcomes to determine the value of 
cancer drugs. Due to the increased cost pressure on payers, such models are 
likely to inspire novel reimbursement schemes for other branded products. 
CONCLUSIONS: Cancer drug reimbursement models are setting new benchmark 
for payers to manage access and control costs. These models have significant 
implications for other expensive branded products.  
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AN ESTIMATE OF THE HEALTH ECONOMIC BURDEN OF UNSATISFACTORY 
CERVICAL CANCER SCREENING TEST SAMPLES IN A POPULATION OF WOMEN 
BETWEEN THE AGES OF 21-65 YEARS IN THE UNITED STATES  
Stone G 
BD, Durham, NC, USA  
OBJECTIVES: Unsatisfactory cervical cancer screening cytology samples (Unsats), 
impose a high financial burden on the health care system. Unsats are important 
because they are more prevalent in women with invasive cervical cancer. The 
purpose of this study is to estimate the impact of Unsats on the cost of cervical 
cancer screening programs as well as on patient outcomes in a U.S. population of 
women. METHODS: A state-transition Markov model was used to simulate 
cervical cancer screening and follow-on treatment for a cohort of 1 million U.S. 
women (21-65 years of age). The screening algorithm used was based on current 
U.S. cervical cancer screening guidelines which call for primary cytology testing 
every 3 years for women between the ages of 21 and 65, with an HPV reflex test 
for those who have an abnormal cytology result. For women over 30, the U.S. 
guidelines recommend the option of a cytology/HPV co-test every 5 years. Other 
inputs included U.S. high-risk HPV prevalence; age-specific cervical cancer 
incidence and associated mortality; age-specific cervical cancer screening and 
treatment compliance; HPV vaccination rates; and U.S. health care resource cost 
data. RESULTS: Unsats are costly to cytology laboratories as all of the costs 
associated with reprocessing these samples must be absorbed by the labs. 
Samples for which reprocessing is unsuccessful impose a greater burden on the 
health care system in terms of the costs associated with patients returning to 
physicians’ offices for a second sample collection. Some patients who should 
return for a second collection are lost to follow-up, presenting an opportunity for 
disease progression. CONCLUSIONS: The Unsat rate associated with a cytology 
test can significantly increase the effective cost of the test. All costs need to be 
considered in order to determine the true cost of a cytology test for cervical 
cancer.  
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OBJECTIVES: For the contemporary health care, creation of patient registries is a 
crucial task; first of all they facilitate, from the evidence-based medicine 
position, the problem of introduction of new effective drugs (including biological 
drugs). The purpose of this study was to describe the first experience of creation 
a breast cancer patient registry in the Russian Federation. METHODS: As of 
24.07.2012, the Registry included 11,960 patients from 16 regions of Russia. The 
proportion of Moscow residents is 49.9%. RESULTS: It is found that only in 9.7% 
of cases included in the Registry breast cancer was detected at stage I. Most 
commonly the diagnosis was established at the following stages: IIA (27.5%), IIB 
(17.1%) and IIIA (19.9%). It is worth noting that in the regions the diagnosis of 
stage I cancer was established more frequently than in Moscow (chi-square=204, 
p<0.000). Assessment of the distribution of patients in the Registry by expression 
of estrogen and progesterone receptors (ER/PR) was performed for only 1195 
(16.7%) of cases where test results were available. Positive HER-2 status was 
found in 14.9% of patients in the Registry. In patients with stage I and stage II, a 
clear prevalence of HER-2 negative cases was found, whereas in patients with 
stage III and stage IV positive status prevailed. Hormonal anti-progesterone 
therapy was given to 1345 patients (94.7% of women with overexpression of 
estrogen and progesterone receptors). 83 patients received treatment with 
trastuzumab. This is consistent with the total number of HER-2 positive patients 
(101); the coverage is equal to 82.2% and considered sufficient. CONCLUSIONS: 
Analysis of the Registry revealed insufficient use of up-to-date immunoassays, 
including estrogens and progesterone receptors typing, it also showed that it is 
early stages of the disease when one can expect better clinical effect from the 
use of hormone therapy and biological therapy.  
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EVALUATION OF DIRECT-TO-CONSUMER ADVERSTISING ACTIVITIES 
CONCERNING HUMAN PAPILLOMA VIRUS VACCINES THROUGH MASS MEDIA 
IN THALAND  
Rattanamahattana M1, Phosi P2 
1Khon Kaen University, Khon Kaen, Thailand, 2Kanthararom Hospital, Sisaket, Thailand  
OBJECTIVES: The educational content of disease awareness raising activities 
concerning Human Papilloma Virus (HPV) vaccine that were targeted directly to 
consumers in Thailand was evaluated in terms of the pattern and quality of the 
advertised activities. METHODS: The activities targeted at Thai consumers 
during January 2006 and December 2008, via various mass media including 
television, magazines, and the internet were identified using health and HPV-
related keywords. The pattern of disease awareness raising activities was 
assessed by using content analysis method while the quality of educational 
content was appraised by two pharmacists using evidence-based publications 
and guidelines from the Cancer Institute of Thailand and medical associations 
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including the product indication registered at the Thai Food and Drug 
Administration. RESULTS: Disease awareness activities were found 47 times in 
various media, of which 48.9% were on the internet, 46.8% in magazines, and 
4.3% in television programs. The main agents of information dissemination were 
government-affiliated organizations (36.7%), medical associations (19.1%), private 
hospitals (12.8%), and the pharmaceutical industry (10.7%), however, 14.9% was 
unidentifiable regarding its origin. The most common pattern of presentation 
was in review or editorial articles and the “fearing appeal” was the most typical 
presentation (59.6%). Nevertheless, 10.6% of the presented data were 
scientifically incorrect according to the evidence-based and claimed data. On 
websites, there was a connection between the sponsoring drug companies of the 
disease awareness activities through the branded logo, the theme color of the 
website, and the product packaging that matched with the specific number the 
HPV strands. Moreover, the hotline contact numbers, which were sponsored by 
the pharmaceutical industry, were also available on the websites and magazines 
for consumers to learn more about cervical cancer. CONCLUSIONS: Disease 
awareness activities are commonly found in Thailand and may pose some due 
concern regarding the misleading claims in the mass media.  
 
PCN147  
NON-TRADITIONAL SCHEMES APPROACH FOR PUBLIC MARKET ACCESS OF 
END-OF-LIFE TREATMENTS IN MEXICAN HEALTH CARE SYSTEM  
Soria-Cedillo IF1, Nevarez A2 
1Sanofi, Mexico City, Mexico, 2Public Health Care System, Mexico City, Mexico  
OBJECTIVES: To estimate budget impact in public health care system in Mexico 
with the use of cabazitaxel in the treatment of metastatic castration-resistant 
prostate cancer (MCRPC) progressing after Docetaxel regimen. METHODS: A risk 
sharing model based on clinical performance of a hypothetical cohort of MCRPC 
patients treated with cabazitaxel was evaluated. The cut-off point was 
determined by median progression free survival <PFS> (according to RECIST 
parameters) reported in TROPIC study. An exponential distribution of patients 
was simulated on a 30-week period with a cross sectional study approach 
considering clinical outcomes for every 3 weeks, a matrix of probabilities of 
transition was created. Median PFS was reported to be 2.8, a cohort of 50 patients 
was evaluated and a length of 10 cycles was assessed. The model considered a 
reimbursement to the institutions when a patient does not reach PFS reported on 
TROPIC study. Direct cost and an institutional perspective were considered. No 
discount rate was included. RESULTS: Estimated budget impact for public 
institutions to cut-off point was estimated in 861,600 USD, with a total 
investment of 1.2 million USD for the estimated number of patients reaching 10 
cycles. Reimbursement based on clinical performance was estimated in 310,200 
USD. Calculated number of patients reaching PFS clinical value was 22 patients. 
Total annual expenditure for public health care institutions of cabazitaxel usage 
under risk sharing scheme, represents 0.002% of public budget for health care 
system and 0.032% of assigned budget for therapeutic goods in main public 
health care institution in Mexico. CONCLUSIONS: Treatment of MCRPC patients 
with Cabazitaxel under a risk sharing agreement may allow patients to obtain 
clinical benefits with a low economic impact to public institutions due to the low 
number of expected patients. Novel schemes for end-of-life treatments must be 
evaluated in order to assess potential benefits for patients/institutions.  
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INFLUENCE OF UROLOGISTS' PRACTICE AFFILIATIONS WITH MEDICAL 
SCHOOLS ON THE USE OF GONADOTROPIN-RELEASING HORMONE AGONISTS 
FOR PROSTATE CANCER PATIENTS IN UNITED STATES  
Quek RGW1, Lin CC2, Master VA3, Virgo KS3, Ward KC4, Portier KM2, Lipsomb J3 
1American Cancer Society, Emory University, Atlanta, GA, USA, 2American Cancer Society, 
Atlanta, GA, USA, 3Emory University, Atlanta, GA, USA, 4Emory University, Rollins School of 
Public Health, Atlanta, GA, USA  
OBJECTIVES: Physician academic affiliations and changes in pharmaceutical 
reimbursement rates have been shown to influence physician practice patterns 
regardless of clinical guidelines, patient clinical or sociodemographic factors. We 
examined the association between urologists’ practice affiliations with medical 
schools and the utilization of gonadotropin-releasing hormone (GnRH) agonists 
before and after reductions in GnRH agonist reimbursement rates resulting from 
the 2003 United States Medicare Modernization Act (MMA). METHODS: Using the 
Surveillance, Epidemiology and End Results–Medicare linked database and the 
American Medical Association Physician Masterfile, we conducted a 
retrospective cohort study of 10,301 patients aged 66 years or older who were 
diagnosed between 2003 and 2005 with localized, low-to-intermediate grade 
prostate cancer, and the 1,577 urologists who saw them. Multilevel regression 
analyses were used to evaluate the influence of urologists’ practice affiliations 
with medical schools on primary GnRH agonist use on patients within 6 months 
of diagnosis – a treatment regimen that is at variance with clinical guidelines 
and has not been shown to improve survival or other patient –centered 
outcomes. RESULTS: Overall, 3763 (37%) patients received GnRH agonists. After 
adjusting for patient, tumor and urologist characteristics, patients who saw 
urologists with no practice affiliation with medical schools were significantly 
more likely to receive GnRH agonists (odds ratio [OR], 2.03; 95% confidence 
interval [95% CI], 1.57-2.63, p<0.0001). Compared to 2003, when the MMA went 
into effect, the odds of receiving GnRH agonists were significantly lower in 2004 
(OR, 0.76; 95% CI, 0.68-0.85, p<0.0001) and 2005 (OR, 0.51; 95% CI, 0.45-0.57, 
p<0.0001). CONCLUSIONS: Even though the overall odds of patients receiving 
unnecessary GnRH agonists decreased after the MMA reimbursement reduction, 
urologists without practice affiliations with medical schools were still 
significantly more likely to prescribe GnRH agonists; such treatment patterns are 
not consistent with patient-centered clinical guidelines and unlikely to have 
significant survival benefit.  
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DETERMINANTS OF INITIAL TREATMENT FOR ADVANCED MELANOMA  
Macahilig CP1, Malinowski FJ1, McGuire M1, Wolthoff P1, Bennett K2, Wong SL2, Penrod JR2 
1Medical Data Analytics, Parsippany, NJ, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA  
We recently described treatment (tx) patterns in a representative real-world 
cohort of U.S. patients (pts) diagnosed with unresectable or metastatic 
melanoma (advanced melanoma [AM]) and found 70 unique regimens observed 
in 689 treated pts (Macahilig 2011). OBJECTIVES: To investigate if there is an 
association between tx choice and patient or practice characteristic(s) in AM. 
METHODS: Data from a random sample of 752 medical charts of newly 
diagnosed AM pts (2004-2008) from 113 US oncologists were collected. In 
analyses of the 689 pts receiving anti-cancer tx, we examined pt characteristics 
of 2 tx categories: pts receiving temozolomide (Tmz) (the most frequently 
prescribed tx) and those not receiving Tmz (“other”). Significance was defined as 
P<0.05. RESULTS: In first-line (FL) tx, pts receiving Tmz were significantly more 
likely to be male and have significantly poorer prognostic characteristics 
including ECOG PS ≥2 (41% vs. 27%); distant disease (85% vs. 68%); more 
metastatic sites (1.9 vs. 1.6); brain metastases (26% vs. 15%); elevated LDH (61% 
vs. 52%); and age ≥65 (58% vs. 41%) compared to the “other” group. FL Tmz pts 
were also significantly more likely to have public primary medical insurance 
(58% vs. 45%). There was no statistical difference in FL use of Tmz versus “other” 
tx in academic versus community practice settings or by physician melanoma 
caseload. CONCLUSIONS: The current study provides evidence that tx choice in 
AM is associated at least in part with pt characteristics.  
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FACTORS ASSOCIATED WITH GUIDELINE-CONCORDANT ADJUVANT THERAPY 
AMONG BREAST CANCER PATIENTS IN RURAL GEORGIA  
Guy Jr. GP1, Lipscomb J1, Gillespie T2, Goodman M1, Richardson LC3, Ward KC1 
1Emory University, Rollins School of Public Health, Atlanta, GA, USA, 2Emory University School  
of Medicine, Atlanta, GA, USA, 3Centers for Disease Control and Prevention, Atlanta, GA,  
USA  
OBJECTIVES: To examine factors associated with the receipt of guideline 
concordant adjuvant chemotherapy, radiation therapy, and hormonal therapy 
among women diagnosed with breast cancer. METHODS: The study population 
consisted of all women residing in a largely rural region of Southwest Georgia 
diagnosed with a first, primary, invasive early-stage (AJCC stage I, II, and IIIA) 
breast cancer from 2001-2003. Predictors of guideline-concordant adjuvant 
therapy, as recommended by the 2000 National Institutes of Health Consensus 
Development Conference Statement, were examined. Factors associated with 
receiving guideline concordance with 1) adjuvant chemotherapy; 2) adjuvant 
radiation therapy; 3) adjuvant hormonal therapy; and 4) all three adjuvant 
therapies jointly were examined using multivariable logistic regression. The 
following variables were examined: patient’s age, race, marital status, insurance 
status, socioeconomic status, urban/rural status, comorbidities, stage at 
diagnosis, grade, hormonal receptor status, treatment site, distance to treatment 
site, and type of surgery performed. Multiple imputation was used to estimate 
missing variable values. RESULTS: Overall, 41% of women were guideline 
concordant for all three adjuvant therapies jointly. Guideline concordance 
ranged from 63%-81% for the individual therapies. After adjustment, higher 
socioeconomic status was associated with guideline concordance for all three 
adjuvant therapies jointly (odds ratio [OR], 3.13, 95% CI, 1.27-7.71), and 
chemotherapy (OR, 3.13, 95% CI, 1.04-9.42) and Medicaid insurance was 
associated with guideline concordant chemotherapy (OR, 4.09; 95% CI, 1.50-
11.20). Being unmarried was associated with nonguideline concordant 
chemotherapy (OR, 0.44; 95% CI, 0.22-0.85) and radiation therapy (OR, 0.47; 95% 
CI, 0.26-0.83). Increased age predicted nonguideline concordance for all three 
adjuvant therapies jointly, chemotherapy, and radiation therapy. The results 
were robust to the use of multiple imputation. CONCLUSIONS: Patient age, 
socioeconomic status, and marital status were independently associated with 
receiving guideline concordant adjuvant therapy. Identifying and addressing 
modifiable factors that lead to non-guideline concordant treatment may reduce 
disparities in treatment and improve cancer outcomes.  
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PREDICTORS OF 2ND AND 3RD LINE CHEMOTHERAPY RECEIPT IN STAGE IV 
COLON CANCER MEDICARE BENEFICIARIES  
Reese ES1, Onukwugha E1, Hanna NN2, Seal B3, Mullins CD1 
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland 
School of Medicine, Baltimore, MD, USA, 3Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, 
USA  
OBJECTIVES: This study examines clinical and demographic predictors of 2ndline 
(Tx2) and subsequent-line (TxS) treatment among elderly Medicare beneficiaries 
diagnosed with metastatic colon cancer (mCC) and initiated treatment. 
METHODS: Using the SEER-Medicare dataset, beneficiaries diagnosed with mCC 
who initiated treatment from 2003-2007 were followed until death or censoring 
in 2009. Treatment lines were classified in combinations of chemotherapy and 
biologics. Logistic regression was used to predict receipt of Tx2 and TxS. 
RESULTS: Among 3266 patients diagnosed with mCC and initiated therapy, 1440 
progressed to Tx2 and 274 progressed to TxS. The strongest predictors of 
progressing to Tx2 was surgery of the primary tumor site (OR: 2.50, 95% CI: 2.16-
2.88) and marital status (OR: 1.66, 95% CI: 1.46-1.90). Older beneficiaries (>80 
years (OR: 0.20, 95% CI: 0.17-0.25) and those with 1-6 months of state buy-in (OR: 
0.31, 95%CI: 0.20-0.49) were less likely to proceed to Tx2. Surgery of the primary 
site was the biggest predictor of receipt of TxS (OR: 2.22, 95%CI: 1.62-2.99). Older 
age (>80 years (OR: 0.27, 95% CI: 0.19-0.39)) and 1-6 months of state buy-in (OR: 
0.17, 95%CI: 0.04-0.69) were the biggest predictors of not proceeding to TxS. 
When compared to the Connecticut registry area, all SEER-registry areas were 
